Suppr超能文献

加拿大肾脏病学会关于 KDIGO 慢性肾脏病评估和管理临床实践指南的评论。

Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management.

机构信息

Department of Medicine, University of Ottawa.

St Joseph's Healthcare, Hamilton; Department of Medicine, McMaster University, Hamilton.

出版信息

Am J Kidney Dis. 2015 Feb;65(2):177-205. doi: 10.1053/j.ajkd.2014.10.013. Epub 2014 Nov 4.

Abstract

We congratulate the KDIGO (Kidney Disease: Improving Global Outcomes) work group on their comprehensive work in a broad subject area and agreed with many of the recommendations in their clinical practice guideline on the evaluation and management of chronic kidney disease. We concur with the KDIGO definitions and classification of kidney disease and welcome the addition of albuminuria categories at all levels of glomerular filtration rate (GFR), the terminology of G categories rather than stages to describe level of GFR, the division of former stage 3 into new G categories 3a and 3b, and the addition of the underlying diagnosis. We agree with the use of the heat map to illustrate the relative contributions of low GFR and albuminuria to cardiovascular and renal risk, though we thought that the highest risk category was too broad, including as it does people at disparate levels of risk. We add an albuminuria category A4 for nephrotic-range proteinuria and D and T categories for patients on dialysis or with a functioning renal transplant. We recommend target blood pressure of 140/90mm Hg regardless of diabetes or proteinuria, and against the combination of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors. We recommend against routine protein restriction. We concur on individualization of hemoglobin A1c targets. We do not agree with routine restriction of sodium intake to <2g/d, instead suggesting reduction of sodium intake in those with high intake (>3.3g/d). We suggest screening for anemia only when GFR is <30mL/min/1.73m(2). We recognize the absence of evidence on appropriate phosphate targets and methods of achieving them and do not agree with suggestions in this area. In drug dosing, we agree with the recommendation of using absolute clearance (ie, milliliters per minute), calculated from the patient's estimated GFR (which is normalized to 1.73m(2)) and the patient's actual anthropomorphic body surface area. We agree with referral to a nephrologist when GFR is <30mL/min/1.73m(2) (and for many other scenarios), but suggest urine albumin-creatinine ratio > 60mg/mmol or proteinuria with protein excretion > 1g/d as the referral threshold for proteinuria.

摘要

我们祝贺 KDIGO(肾脏病:改善全球预后)工作组在广泛的主题领域所做的全面工作,并赞同他们在慢性肾脏病评估和管理临床实践指南中的许多建议。我们同意 KDIGO 对肾脏疾病的定义和分类,并欢迎在所有肾小球滤过率 (GFR) 水平增加白蛋白尿类别,用 G 类别而非分期来描述 GFR 水平,将前 3 期分为新的 G 类别 3a 和 3b,并增加潜在诊断。我们同意使用热图来说明低 GFR 和白蛋白尿对心血管和肾脏风险的相对贡献,尽管我们认为最高风险类别过于宽泛,包括风险水平不同的人群。我们增加了一个白蛋白尿类别 A4 用于肾病范围蛋白尿,以及用于透析或有功能肾移植患者的 D 和 T 类别。我们建议无论是否患有糖尿病或蛋白尿,目标血压均为 140/90mmHg,并反对血管紧张素受体阻滞剂与血管紧张素转换酶抑制剂联合使用。我们建议不要常规限制蛋白质摄入。我们同意个体化血红蛋白 A1c 目标。我们不同意常规限制钠摄入量至<2g/d,而是建议减少高钠摄入量(>3.3g/d)患者的钠摄入量。我们建议仅在 GFR<30mL/min/1.73m(2) 时筛查贫血。我们认识到缺乏关于适当磷酸盐目标和实现这些目标的方法的证据,因此不同意这方面的建议。在药物剂量方面,我们同意推荐使用根据患者估计的 GFR(标准化为 1.73m(2))和患者实际人体表面积计算得出的绝对清除率(即毫升/分钟)。当 GFR<30mL/min/1.73m(2) 时(以及许多其他情况),我们同意转介给肾病医生,但建议将尿白蛋白/肌酐比值>60mg/mmol 或蛋白尿蛋白排泄量>1g/d 作为蛋白尿的转介阈值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验